The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy
- 1 April 1999
- journal article
- clinical trial
- Published by Elsevier in International Journal of Cardiology
- Vol. 69 (1) , 77-82
- https://doi.org/10.1016/s0167-5273(99)00008-x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor-α Promote Progressive Left Ventricular Dysfunction and Remodeling in RatsCirculation, 1998
- Cardiac Failure in Transgenic Mice With Myocardial Expression of Tumor Necrosis Factor-αCirculation, 1998
- Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-αCirculation Research, 1997
- Elevated soluble CD14 receptors and altered cytokines in chronic heart failureThe American Journal of Cardiology, 1997
- Cytokines and Cardiac Contractile FunctionCirculation, 1997
- The Clinical Relevance of Circulating Tumor Necrosis Factor-α in Acute Decompensated Chronic Heart Failure Without CachexiaChest, 1996
- Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human HeartCirculation, 1996
- Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration.Journal of Clinical Investigation, 1995
- Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.Circulation, 1994
- Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.Heart, 1991